Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line

doi:10.3748/wjg.14.5403

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4398)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

379

HTML

3513

Figures (1-6)

310

Tables (1-2)

196

Sum=4398

Sep 21, 2008 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Sep 21, 2008; 14(35): 5403-5411
Published online Sep 21, 2008. doi: 10.3748/wjg.14.5403

Full Size Figure Download Figure

Figure 3 A: Effect of erlotinib on mean tumor volume in the BxPC-3 xenograft model. Mice were implanted with BxPC-3 cells. When palpable tumors were established, animals were randomly divided into two groups. The animals were continuously gavaged with the agents for 4 wk as described in Matericals and Methods. Tumor size was measured twice per week. Values are means, n = 6. B: Mice of control group; C: Mice of erlotinb group.

Citation: Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14(35): 5403-5411
URL: https://www.wjgnet.com/1007-9327/full/v14/i35/5403.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5403